CHICAGO, May 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that it held its Annual Meeting of Shareholders yesterday at its Woodridge headquarters.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
At the meeting, the shareholders elected Dr. Michael T. Flavin and Messrs. Scott F. Meadow and Thomas V. Thornton to the Company's Board of Directors each for a term of three years and ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2008. The shareholders also approved the amendment of the Company's stock incentive plan to provide 1,900,000 additional stock options for future grant by the Company to attract and retain talented professionals and achieve continued success and growth.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage development for the treatment of respiratory tract infections. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for historical information, the statements made in this press release are forward-looking statements about Advanced Life Sciences Holdings, Inc., including statements regarding the clinical trials and regulatory pathway of cethromycin. Forward-looking statements represent our management's judgment regarding future events and are accurate at the time they are made. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, capital requirements, and our ability to access capital through partnerships, stock offerings and future revenues; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
